Physicians' Academy for Cardiovascular Education

Diabetes & CVD

Diabetes type II confers an increased CVD risk. Recent scientific developments have yielded antidiabetic agents that positively impact CV risk in diabetic patients. Follow the latest insights into the close link between diabetes and CVD.

Mendelian randomization confirms association BMI and cardio-metabolic diseases

July 14, 2017 - Lyall DM, et al. - JAMA Cardiology 2017

NT–proBNP has additive predictive value for heart failure in diabetic patients

July 12, 2017 - Ohkuma T, et al. - Diabetes Care. 2017

GLP-1 analogue approved by FDA for CV risk reduction in diabetes

June 28, 2017 - news

BET inhibition in renal and cardiovascular disease: What is the clinical roadmap?

June 5, 2017 - ERA-EDTA, Madrid Spain - Kamyar Kalantar-Zade, MD UC Irvine School of Medicine Irvine, Ca, USA

Molecular mechanisms involved in the beneficial effect of BET inhibition in experimental renal disease

June 5, 2017 - ERA-EDTA, Madrid Spain - Marta Ruiz-Ortega – Fundación Jiménez Díaz, Madrid, Spain

The high risk diabetes patient: What is the need for novel approaches to reduce cardiovascular and renal risk?

June 5, 2017 - ERA-EDTA, Madrid Spain - Luis M Ruilope, MD – Hospital 12 de Octubre, Madrid, Spain

UK: Clinical Dialogues: Lipids & Diabetes 2017

Dec. 7, 2017 - Stratford Upon Avon, United Kingdom - Prof Peter Sever

How incretin therapy changes diabetes and prediabetes management

May 22, 2017

Type of glycemic control is more important than tight glycemic control

May 1, 2017 - ESC HF 2017, Paris

Challenges in Heart Failure management: Diabetes and Renal Impairment

May 12, 2017 - Paris, France - Martin Cowie, MD - ESC Heart Failure, Paris

SGLT2 inhibition & Heart Failure: Lessons from EMPA REG Outcome

May 9, 2017 - Paris, France - Per-Henrik Groop, MD - ESC Heart Failure, Paris

New diabetes drugs and heart failure: What have we learnt?

May 6, 2017 - Paris, France - John McMurray, MD - ESC Heart Failure, Paris

New diabetes treatments with CV benefit: A changing role for the cardiologist

Apr. 19, 2017 - Robert J Chilton, MD (San Antonio, TX, USA)

Modifying CV risk by managing diabetes

Nov. 12, 2016 - New Orleans, LA, USA - Jorge Plutzky, MD (Boston, MA, USA)

What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?

Aug. 29, 2016 - ESC Rome, Italy - Prof. Silvio E Inzucchi (New Haven, CT, USA)

HF & Diabetes: SGLT2 inhibition a paradigm shift?

Aug. 29, 2016 - ESC 2016, Rome, Italy - John McMurray, MD University of Glasgow United Kingdom - Recorded at PACE-CME symposium held during ESC 2016 in Rome

Challenging cardiovascular risk in diabetes: ready for a new approach?

Aug. 29, 2016 - John Deanfield, MD, University College London, United Kingdom

Overview of SGLT-2 inhibitors in T2DM management: current position & future promise

Aug. 29, 2016 - ESC, Rome Italy - Silvio Inzucchi, MD, Yale Diabetes Center, New Haven, CT, USA - PACE-CME symposium held at ESC 2016, Rome

The high risk diabetes patient with cardiovascular disease: What else can we target to reduce cardiovascular risk?

Aug. 28, 2016 - ESC 2016, Rome - Kausik Ray, MD – Imperial College London, United Kingdom - Recorded at PACE-CME symposium at ESC 2016
##SCROLLER_ITEMS_FULL_TITLE##

The effect of treatment with DPP-4 inhibition on renal complications in diabetic patients.

Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)
##SCROLLER_ITEMS_FULL_TITLE##

A changing treatment paradigm in diabetes

July 30, 2016 - Bangkok, Thailand - Richard E. Pratley, MD (Florida Hospital Diabetes Institute, Orlando, FL, USA)

SGLT2 inhibition in diabetic kidney disease

Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)
##SCROLLER_ITEMS_FULL_TITLE##

Exciting times in diabetes treatment: new drug class moves beyond glucose reduction

Apr. 23, 2016 - Kuala Lumpur - Naveed Sattar - University of Glasgow, United Kingdom

Heart failure and SGLT2 inhibition: understanding the mechanism for potential benefit

May 21, 2016 - ESC HF 2016, Florence, Italië - Naveed Sattar, MD - Glasgow Universtiy, Glasgow, UK

Hyperkalemia: Novel treatment strategies to manage potassium levels in heart failure

May 23, 2016 - ESC HF 2016, Florence, Italy - Peter van der Meer, MD - UMCG Groningen, The Netherlands

SGLT2 inhibition and cardiovascular outcomes: lessons from recent clinical trials

May 21, 2016 - ESC HF 2016, Florence, Italy - David Fitchett, MD - University of Toronto, ONT, Canada

Current treatment of Diabetes in Heart Failure

May 21, 2016 - ESC HF 2016, Florence, Italy - Adriaan Voors, MD - UMCG Groningen, The Netherlands

New therapies for type 2 diabetes show CV benefit beyond their glucose-lowering effect

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Silvio E. Inzucchi, MD - New Haven, CT, USA
##SCROLLER_ITEMS_FULL_TITLE##

The EMPA REG Outcome trial: The challenge for cardiologists in managing T2DM

May 10, 2016 - David Fitchett, MD, University of Toronto, Canad

CV protection by SGLT2 inhibition: Potential mechanisms for benefit

May 10, 2016 - Kuala Lumpur, Malaysia - Prof Hiddo Lambers Heerspink, Groningen, The Netherlands
##SCROLLER_ITEMS_FULL_TITLE##

Review of cardiovascular safety of DPP4 inhibitors

May 6, 2016 - Dubai, UAE - Dr Sanjay Rajagopalan, MD, Maryland
##SCROLLER_ITEMS_FULL_TITLE##

Stroke reduction with PPAR-Y antagonist pioglitazone

May 6, 2016 - Dubai, UAE - Dr Robert J Chilton
##SCROLLER_ITEMS_FULL_TITLE##

Diabetic dyslipidaemia and residual risk in the era of LDL control

Mar. 21, 2016 - Boston, MA, USA - Aruna Pradhan

Mendelian randomization confirms association BMI and cardio-metabolic diseases

A Mendelian Randomization Study

July 14, 2017 - Lyall DM, et al. - JAMA Cardiology 2017

In a large population-based cohort study, BMI was associated with risk of hypertension, CHD, T2DM, elevated SBP and DBP based on causal mendelian randomization estimates, but not with stroke or pulse rate.

NT–proBNP has additive predictive value for heart failure in diabetic patients

July 12, 2017 - Ohkuma T, et al. - Diabetes Care. 2017

In diabetic patients at high cardiovascular risk, markers IL-6, hs-CRP, hs-cTnT and NT-proBNP were independent predictors of heart failure, while NT-proBNP also had an additive predictive value.

GLP-1 analogue approved by FDA for CV risk reduction in diabetes

June 28, 2017 - news

Based on the results of the LEADER trial, GLP-1 analogue liraglutide is approved by the FDA for CV risk reduction in type 2 diabetes

Some traditional Chinese medicine may help control CV risk factors and improve CVD

June 14, 2017 - Hao P et al., - J Am Coll Cardiol. 2017
Systematic review of RCT evidence suggests that some TCM medications might improve CV risk factors and some may exert beneficial effects on ASCVD and chronic HF. Not all studies are of high methodological quality.

Systematic review of RCT evidence suggests that some TCM medications might improve CV risk factors and some may exert beneficial effects on ASCVD and chronic HF. Not all studies are of high methodological quality.

New data including real-world CV outcomes with SGLT2 inhibitor support its safety profile

June 13, 2017 - news
Updated analysis provides evidence on the safety profile of dapagliflozin, including no imbalance in lower-limb amputations, and CVD-REAL analyses compare CV outcomes on SGLT2 inhibition with DPP4 inhibition.

ADA 2017 Updated analysis provides evidence on the safety profile of dapagliflozin, including no imbalance in lower-limb amputations, and CVD-REAL analyses compare CV outcomes on SGLT2 inhibition with DPP4 inhibition.

Novel SGLT2 inhibitor improves glycemic control in T2DM

June 13, 2017 - news
The investigational SGLT2 inhibitor ertugliflozin improved glycemic control in adults with type 2 diabetes. HbA1c reduced when combined with sitagliptin or metformin.

ADA 2017 The investigational SGLT2 inhibitor ertugliflozin improved glycemic control in adults with type 2 diabetes. HbA1c reduced when combined with sitagliptin or metformin.

Fewer CV events but higher risk of amputation with SGLT2 inhibitor in T2DM patients

June 13, 2017 - Neal B et al, for the CANVAS Program Collaborative Group - NEJM 2017

In the CANVAS trial program, diabetic patients with an increased CV risk treated with SGLT2 inhibitor canagliflozin had a significantly lower risk of CV events and a higher risk of amputation, compared with placebo.

New, long-acting insulin is safe and lowers the rate of severe and nocturnal hypoglycemia events

June 13, 2017 - news
The DEVOTE trial compared injections of the long-acting insulin degludec with insulin glargine in high-risk T2DM adults and found degludec to be non-inferior for MACE.

ADA 2017 The DEVOTE trial compared injections of the long-acting insulin degludec with insulin glargine in high-risk T2DM adults and found degludec to be non-inferior for MACE.

GLP-1 analogue reduces CV risk in people with T2DM regardless of severe hypoglycemia events

June 13, 2017 - news
New LEADER analysis shows that liraglutide lowered risk of major CV events in T2DM patients at high CV risk, even if they had severe hypoglycemia. Hypoglycemia occurred less often with liraglutide.

ADA 2017 New LEADER analysis shows that liraglutide lowered risk of major CV events in T2DM patients at high CV risk, even if they had severe hypoglycemia. Hypoglycemia occurred less often with liraglutide.

PCSK9 inhibitor safely improves lipid profile in high-risk patients with type 2 diabetes

June 12, 2017 - news
Results of two ODYSSEY studies with alirocumab were presented at the ADA Scientific Sessions, showing that alirocumab lowers LDL-c in patients with T2D, similar to those without T2DM.

ADA 2017 Results of two ODYSSEY studies with alirocumab were presented at the ADA Scientific Sessions, showing that alirocumab lowers LDL-c in patients with T2D, similar to those without T2DM.

Meeting Impression: Heart failure, Diabetes, and Renal Dysfunction: Time for a more unified approach

May 1, 2017 - news
During a satellite symposium at ESC Heart Failure 2017 in Paris, the increased CV risk in diabetic patients with HF was discussed, and which novel treatments can be considered in these patients.

During a satellite symposium at ESC Heart Failure 2017 in Paris, organised by PACE-CME, the increased CV risk in diabetic patients with HF was discussed, and which novel treatments can be considered in these patients.

Metformin may protect against coronary atherosclerosis in men with prediabetes

June 9, 2017 - Goldberg RB et al., - Circulation 2017

In a large Diabetes Prevention Program, men with prediabetes treated with metformin for an average duration of 14 years had lower coronary calcium scores compared with the placebo group.